Mazur is scheduled to present and facilitate one-on-one sessions at the 2026 Maxim Growth Summit, running October 12–14 at the Hard Rock Hotel. He will follow this with an appearance at the ThinkEquity Conference on October 15 at the Mandarin Oriental, where a formal presentation is slated for 3:00 p.m. ET. These engagements serve as a platform to discuss the performance of LYMPHIR, the targeted immunotherapy launched in late 2025 by the company’s majority-owned subsidiary, Citius Oncology. Beyond the oncology sector, Citius maintains a late-stage pipeline that includes the catheter salvage solution Mino-Lok and the hemorrhoid treatment CITI-002, both of which have completed pivotal trials. The company is currently coordinating with the FDA to determine the regulatory path forward for these programs.